Actively Recruiting
Study of Individuals and Families With Aberrations in DDX41 or Similar Cancer Predisposition Variants
Led by National Cancer Institute (NCI) · Updated on 2026-04-30
510
Participants Needed
1
Research Sites
516 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Background: Hereditary hematopoietic malignancy (HHM) syndromes are a group of inherited disorders that raises the risk of blood cancers. Many people with HHMs have changes in a gene (DDX41) that makes it more likely that they will develop myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), or other cancers. This natural history study will explore the link between HHM syndromes and these diseases. Objective: To study the link between HHM and MDS/AML. Eligibility: People aged 1 month and older with HHM. Relatives with HHM are also needed. Design: Participants aged 3 years and older will have 1 initial clinic visit with the option to follow-up annually. They will undergo these procedures: They will have a physical exam with blood and urine tests. They may give samples of saliva, stool, nails, and skin. Their ability to do normal activities will be reviewed. Some may have a bone marrow biopsy: A tissue sample will be drawn from inside a bone. They may answer questions about their health and family medical history. Participants younger than 3 years, and those who cannot come to the clinic, will be contacted by phone or email. Their samples may be collected locally and sent to researchers. For participants who have changes in their DDX41 gene: Researchers will contact them or their primary care provider once a year for 10 years. Researchers will check on participants health and collect any new test results. Some may be asked to send new samples. Participants who do not have changes in their DDX41 gene may be contacted yearly, or less often, for 10 years. Some participants may be asked to return to the clinic if needed.
CONDITIONS
Official Title
Study of Individuals and Families With Aberrations in DDX41 or Similar Cancer Predisposition Variants
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age greater than 1 month old
- Participants with confirmed aberrations affecting the DDX41 gene, DDX41 RNA, or DDX41 protein
- Participants with confirmed aberrations in another hereditary hematopoietic malignancy (HHM) variant
- Participants without HHM variants who have a first or second degree relative with confirmed or suspected HHM variants
- Participants must have a healthcare provider outside NIH managing their care and diagnostic findings
- Ability to understand and willingness to sign a written consent document
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
National Institutes of Health Clinical Center
Bethesda, Maryland, United States, 20892
Actively Recruiting
Research Team
R
Rebecca B Alexander
CONTACT
S
Sung-Yun Pai, M.D.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here